AbbVie's Growth Engine Is Scaling Faster Than The Street Expects
AbbVie is reporting accelerating top-line momentum from its immunology franchise while generating substantial free cash flow and paying a reliable dividend. With Q1 revenue of $15.0B, combined Skyrizi and Rinvoq sales now forecast above $31B in 2026, and $17.8B of free cash flow on the balance sheet, the setup supports a long trade at $207.10 with …